Rifaximin for preventing episodes of overt hepatic encephalopathy

Rifaximin is recommended, within its marketing authorisation, as an option for reducing the recurrence of episodes of overt hepatic encephalopathy in people aged 18 years or older. The recommended dose for this indication is 550mg twice daily.